ATE284694T1 - Uracilderivate enthaltende krebsmetastasen inhibitoren - Google Patents
Uracilderivate enthaltende krebsmetastasen inhibitorenInfo
- Publication number
- ATE284694T1 ATE284694T1 AT97940448T AT97940448T ATE284694T1 AT E284694 T1 ATE284694 T1 AT E284694T1 AT 97940448 T AT97940448 T AT 97940448T AT 97940448 T AT97940448 T AT 97940448T AT E284694 T1 ATE284694 T1 AT E284694T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer metastases
- unsubstituted
- inhibitors containing
- substituted
- uracil derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25130396 | 1996-09-24 | ||
| PCT/JP1997/003355 WO1998013045A1 (fr) | 1996-09-24 | 1997-09-22 | Inhibiteurs de metastases cancereuses contenant des derives d'uracile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE284694T1 true ATE284694T1 (de) | 2005-01-15 |
Family
ID=17220808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97940448T ATE284694T1 (de) | 1996-09-24 | 1997-09-22 | Uracilderivate enthaltende krebsmetastasen inhibitoren |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6255314B1 (de) |
| EP (1) | EP0884051B1 (de) |
| JP (1) | JP3088758B2 (de) |
| KR (1) | KR100284413B1 (de) |
| AT (1) | ATE284694T1 (de) |
| AU (1) | AU699728B2 (de) |
| CA (1) | CA2238331C (de) |
| DE (1) | DE69731940T2 (de) |
| DK (1) | DK0884051T3 (de) |
| ES (1) | ES2235249T3 (de) |
| PT (1) | PT884051E (de) |
| WO (1) | WO1998013045A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4049477B2 (ja) * | 1999-03-23 | 2008-02-20 | 大鵬薬品工業株式会社 | 副作用軽減剤 |
| FR2796945B1 (fr) * | 1999-07-30 | 2002-06-28 | Sod Conseils Rech Applic | Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments |
| NZ523970A (en) * | 2003-02-04 | 2005-02-25 | Ind Res Ltd | Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases |
| US8415315B2 (en) | 2004-05-06 | 2013-04-09 | University Of Central Florida Research Foundation, Inc. | Methods and compositions for inhibiting the proliferation of cancer cells |
| PT1849470T (pt) * | 2005-01-26 | 2017-09-22 | Taiho Pharmaceutical Co Ltd | Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase |
| US7799783B2 (en) | 2005-01-26 | 2010-09-21 | Taiho Pharmaceutical Co., Ltd. | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| JP5058156B2 (ja) * | 2006-04-13 | 2012-10-24 | 大鵬薬品工業株式会社 | 炎症性腸疾患治療薬 |
| EP2036903B1 (de) * | 2006-06-30 | 2012-05-23 | Taiho Pharmaceutical Co., Ltd. | Potentiator für die strahlentherapie |
| TWI429439B (zh) * | 2007-10-11 | 2014-03-11 | Taiho Pharmaceutical Co Ltd | And a therapeutic agent for inflammatory bowel disease using a uracil derivative as an active ingredient |
| TWI435725B (zh) | 2007-10-11 | 2014-05-01 | Taiho Pharmaceutical Co Ltd | The use of a uracil compound for a prophylactic or therapeutic composition for the preparation of cystitis and hepatitis |
| JP2010202591A (ja) * | 2009-03-04 | 2010-09-16 | Hokkaido Univ | 増殖性疾患の内用放射線治療剤 |
| WO2014185528A1 (ja) | 2013-05-17 | 2014-11-20 | 大鵬薬品工業株式会社 | Ｔｋ１タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法 |
| LT3012255T (lt) | 2013-06-17 | 2021-12-27 | Taiho Pharmaceutical Co., Ltd. | Stabili tipiracilo hidrochlorido kristalinė forma ir jo kristalizacijos būdas |
| CN105906573A (zh) * | 2015-12-23 | 2016-08-31 | 嘉实（湖南）医药科技有限公司 | 一种替吡嘧啶中间体的制备方法 |
| AR109950A1 (es) * | 2016-10-14 | 2019-02-06 | Tes Pharma S R L | INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3450399B2 (ja) * | 1993-12-28 | 2003-09-22 | 大鵬薬品工業株式会社 | 血管新生阻害剤 |
| CA2191340C (en) * | 1995-03-29 | 2001-04-17 | Shingo Yano | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same |
-
1997
- 1997-09-22 CA CA002238331A patent/CA2238331C/en not_active Expired - Fee Related
- 1997-09-22 DK DK97940448T patent/DK0884051T3/da active
- 1997-09-22 AU AU42225/97A patent/AU699728B2/en not_active Ceased
- 1997-09-22 US US09/077,209 patent/US6255314B1/en not_active Expired - Lifetime
- 1997-09-22 DE DE69731940T patent/DE69731940T2/de not_active Expired - Lifetime
- 1997-09-22 ES ES97940448T patent/ES2235249T3/es not_active Expired - Lifetime
- 1997-09-22 PT PT97940448T patent/PT884051E/pt unknown
- 1997-09-22 AT AT97940448T patent/ATE284694T1/de active
- 1997-09-22 WO PCT/JP1997/003355 patent/WO1998013045A1/ja active IP Right Grant
- 1997-09-22 JP JP10503999A patent/JP3088758B2/ja not_active Expired - Fee Related
- 1997-09-22 EP EP97940448A patent/EP0884051B1/de not_active Expired - Lifetime
- 1997-09-22 KR KR1019980703452A patent/KR100284413B1/ko not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU699728B2 (en) | 1998-12-10 |
| KR19990067441A (ko) | 1999-08-16 |
| AU4222597A (en) | 1998-04-17 |
| KR100284413B1 (ko) | 2001-03-02 |
| PT884051E (pt) | 2005-03-31 |
| US6255314B1 (en) | 2001-07-03 |
| CA2238331C (en) | 2003-02-25 |
| EP0884051A4 (de) | 2001-06-13 |
| DE69731940D1 (de) | 2005-01-20 |
| DK0884051T3 (da) | 2005-01-24 |
| CA2238331A1 (en) | 1998-04-02 |
| JP3088758B2 (ja) | 2000-09-18 |
| WO1998013045A1 (fr) | 1998-04-02 |
| ES2235249T3 (es) | 2005-07-01 |
| DE69731940T2 (de) | 2005-05-25 |
| EP0884051B1 (de) | 2004-12-15 |
| EP0884051A1 (de) | 1998-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE284694T1 (de) | Uracilderivate enthaltende krebsmetastasen inhibitoren | |
| MX9203551A (es) | Derivados de fenil amidinas utiles como inhibidores de agregacion de plaquetas. | |
| MXPA02011974A (es) | Derivados de quinazolina sustituidos y su uso como inhibidores. | |
| ATE345122T1 (de) | Stabile emulsionszubereitungen | |
| CY1107001T1 (el) | Αζωτουχα ετεροκυκλικα παραγωγα καρβοξαμιδιου ή αλας αυτων ως αντιϊκοι παραγοντες | |
| MY133473A (en) | Haterocyclic glycyl beta-alanine derivatives. | |
| NO20004485D0 (no) | Sykloalkenderivater, deres fremstilling og anvendelse | |
| DK0715623T3 (da) | Blodpladeaggregationsinhibitorer | |
| TR200403436T2 (tr) | Kristalin 1-metilkarbapenem türevleri. | |
| WO2003049690A3 (en) | Hiv integrase inhibitors | |
| DE60014043D1 (de) | Flouride von 4-substituierten piperidin-derivaten | |
| DE69824450D1 (de) | Biphenylamidin-derivate | |
| DE60104697D1 (de) | Sulfonamid-derivate | |
| DE60330758D1 (de) | Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen | |
| DK1209151T3 (da) | 4-substituerede piperidinderivativer | |
| ATE194621T1 (de) | Pyrazolothiazolopyrimidin-derivate | |
| FI940171A0 (fi) | Ketorolaakkijohdannaisia, joiden gastrointestinaalinen ärsytys ja ulserointi ovat huomattavasti vähentyneet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0884051 Country of ref document: EP |